Merck & Co., Inc. MRK

Full chart Compare
Set alert

Price alert · MRK

All alert types
149.99 USD +5.32 (+3.68%)

Nov 4, 2026, 3:58 PM EST

146.05 Day range 150.32
83.86 52-week range 156.45
YTD
+42.49%
1 year
+78.86%
Market cap
370.22B
Revenue (ttm)
67.38B
Profit margin
3.64%
EPS (ttm)
0.99
Shares out
2.47B
P/E ratio
151.58
Forward P/E
16.03
Dividend
3.40 (2.41%)
Ex-dividend date
Sep 14, 2026
YTD return
+42.49%
1-year return
+78.86%
Volume
6.30M
Avg volume
10.29M
Open
148.54
Previous close
144.67
Day's range
146.05 – 150.32
52-week range
83.86 – 156.45
Beta
0.12
Analysts
Buy
Price target
160.29 (+6.9%)
Earnings date
Feb 2, 2027

YTD +43.03 (+40.42%)

120140160Feb 3Apr 6Jun 5Aug 6Oct 6149.48

Key statistics

Enterprise value
412.85B
PEG ratio
2.80
Price / sales
5.30
Price / book
8.52
Dividend yield
2.29%
Payout ratio
266.67%
Revenue growth
4.70%
Free cash flow
0
Total cash
7.14B
Total debt
53.91B
Return on equity
0.00%
Short % of float
1.09%
50-day average
146.78
200-day average
126.89

Financials — quick view

All financials
MRK Revenue — quarterly 16.61B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRK Net income — quarterly -1.33B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRK EPS — quarterly -0.54
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MRK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 2, 2027Dec 30, 20261.77———
Oct 29, 2026Sep 30, 20262.092.49+0.40+19.14%
Aug 4, 2026Jun 30, 2026-0.27049-0.13+0.14+51.94%
Apr 30, 2026Mar 31, 2026-1.47-1.28+0.19+12.93%
Feb 3, 2026Dec 31, 20252.012.04+0.03+1.49%
Oct 30, 2025Sep 30, 20252.362.58+0.22+9.32%

Upgrades / downgrades

MRK analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026Freedom BrokermainHoldHold
Nov 2, 2026Cantor FitzgeraldmainNeutralNeutral
Oct 30, 2026JP MorganmainOverweightOverweight
Oct 30, 2026RBC CapitalmainSector PerformSector Perform
Oct 30, 2026GuggenheimmainBuyBuy
Oct 26, 2026BarclaysmainOverweightOverweight

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
merck.com

News

Your note

Sign in to keep a note on MRK — it syncs with the Stock Master app.

Insider holders

MRK insider holders
InsiderRelationLatest transactionDateShares held
CHATTOPADHYAY SANATOfficerConversion of Exercise of derivative securityApr 28, 2026200,675
DAVIS ROBERT MChief Executive OfficerConversion of Exercise of derivative securityApr 28, 2026450,351
DELUCA RICHARD ROBERT JR.OfficerSaleAug 11, 2026110,167
GUINDO CHIRFIOfficerSaleAug 12, 202636,613
LI DEAN YOfficerConversion of Exercise of derivative securityApr 28, 202694,431
LITCHFIELD CAROLINEChief Financial OfficerConversion of Exercise of derivative securityApr 28, 202692,300

Institution ownership

MRK institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.20%226,999,83732.84BJun 29, 2026
Vanguard Capital Management LLC6.54%161,323,17423.34BJun 29, 2026
State Street Corporation4.88%120,413,25617.42BJun 29, 2026
Wellington Management Group, LLP3.50%86,249,28312.48BJun 29, 2026
Vanguard Portfolio Management LLC2.75%67,738,9699.80BJun 29, 2026
Geode Capital Management, LLC2.46%60,744,2148.79BJun 29, 2026

Fund ownership

MRK fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%78,411,37411.34BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%63,996,8849.26BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF1.47%36,188,6065.24BAug 30, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%32,874,3674.76BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%32,060,5434.64BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%30,514,3124.41BSep 29, 2026